Respiratorius AB

Respiratorius is a research company focused on the development of drug candidates for the treatment of cancer, and especially aggressive lymphoma. The company was established in 1999 as a spin-off from Lund University. The operations are located in Sweden, where research is conducted in-house, but also through international partners. The company has its headquarters in Lund.

Quotes for Respiratorius AB

Board

CEO

Johan Drott

Chairperson of the Board

Ingemar Kihlström

Board

Carl-Magnus Schultz
Johan Drott
Mia Lundblad

Articles of association

Videos

1 / 4

CompanyPresentation Bolagspresentation och Q&A med Johan Drott

CompanyPresentation Johan Drott CEO presenterar på Life Science Day 2019

CompanyPresentation Johan Drott CEO, presenterar på Redeye Investor Forum - 10 sep

CompanyPresentation Johan Drott, CEO Respiratorius

** Powered by Modular Finance

*Powered by Modular Finance

Key Numbers

	2026-06-30	2026-03-31	2025-12-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Number of months that the report spans	Q2 3 Months	Q1 3 Months	2025	Q4 3 Months	Q3 3 Months	Q2 3 Months	Q1 3 Months
Total revenue MSEK	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Earnings before interest and tax MSEK	-1.78	-1.73	-6.95	-1.70	-1.45	-1.81	-2.01
Profit before tax MSEK	-1.78	-1.73	-6.95	-1.70	-1.45	-1.81	-2.01
Net profit MSEK	-1.78	-1.73	-6.95	-1.70	-1.45	-1.81	-2.01
Earnings per share SEK	-0.23	-0.21	-1.17	-0.21	-0.18	-0.35	-0.39
Dividend per share SEK	0,00	0,00	0.00	0.00	0,00	0,00	0,00
Equity MSEK	27.10	28.87	30.61	30.61	32.29	26.28	28.09
Fixed assets MSEK	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Intangible assets MSEK	24.17	24.76	24.27	24.27	24.19	24.12	24.08
Current assets MSEK	3.20	5.04	7.65	7.65	9.01	3.22	5.32
Total asset MSEK	27.37	29.80	31.92	31.92	33.20	27.35	29.40
Long term liabilities MSEK	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Current liabilities MSEK	0.27	0.92	1.31	1.31	0.91	1.06	1.31
Number of shares SEK	7902748.00	7902748.00	7902748.00	7902748.00	7902748.00	5098548.00	5098548.00